Inserm, U913, Nantes, F-44093, France.
Neurobiol Dis. 2013 Feb;50:42-8. doi: 10.1016/j.nbd.2012.09.007. Epub 2012 Sep 24.
Lewy pathology affects the gastrointestinal tract in Parkinson's disease (PD) and data from recent genetic studies suggest a link between PD and gut inflammation. We therefore undertook the present survey to investigate whether gastrointestinal inflammation occurs in PD patients. Nineteen PD patients and 14 age-matched healthy controls were included. For each PD patients, neurological and gastrointestinal symptoms were assessed using the Unified Parkinson's Disease Rating Scale part III and the Rome III questionnaire, respectively and cumulative lifetime dose of L-dopa was calculated. Four biopsies were taken from the ascending colon during the course of a total colonoscopy in controls and PD patients. The mRNA expression levels of pro-inflammatory cytokines (tumor necrosis factor alpha, interferon gamma, interleukin-6 and interleukin-1 beta) and glial marker (Glial fibrillary acidic protein, Sox-10 and S100-beta) were analyzed using real-time PCR in two-pooled biopsies. Immunohistochemical analysis was performed on the two remaining biopsies using antibodies against phosphorylated alpha-synuclein to detect Lewy pathology. The mRNA expression levels of pro-inflammatory cytokines as well as of two glial markers (Glial fibrillary acidic protein and Sox-10) were significantly elevated in the ascending colon of PD patients with respect to controls. The levels of tumor necrosis factor alpha, interferon gamma, interleukin-6, interleukin-1 beta and Sox-10 were negatively correlated with disease duration. By contrast, no correlations were found between the levels of pro-inflammatory cytokines or glial markers and disease severity, gastrointestinal symptoms or cumulative lifetime dose of L-dopa. There was no significant difference in the expression of pro-inflammatory cytokines or glial marker between patients with and without enteric Lewy pathology. Our findings provide evidence that enteric inflammation occurs in PD and further reinforce the role of peripheral inflammation in the initiation and/or the progression of the disease.
路易体病理影响帕金森病(PD)的胃肠道,最近的遗传研究数据表明 PD 与肠道炎症之间存在关联。因此,我们进行了本研究以调查 PD 患者是否存在胃肠道炎症。纳入 19 名 PD 患者和 14 名年龄匹配的健康对照者。对于每位 PD 患者,使用统一帕金森病评定量表第 III 部分和罗马 III 问卷分别评估其神经和胃肠道症状,并计算累积左旋多巴剂量。在对照者和 PD 患者的全结肠镜检查过程中,从升结肠取 4 份活检。使用实时 PCR 分析两 pooled 活检中促炎细胞因子(肿瘤坏死因子-α、干扰素-γ、白细胞介素-6 和白细胞介素-1β)和神经胶质标志物(胶质纤维酸性蛋白、Sox-10 和 S100-β)的 mRNA 表达水平。使用针对磷酸化α-突触核蛋白的抗体对剩余的两部分活检进行免疫组织化学分析,以检测路易体病理。与对照者相比,PD 患者升结肠中促炎细胞因子以及两种神经胶质标志物(胶质纤维酸性蛋白和 Sox-10)的 mRNA 表达水平显著升高。肿瘤坏死因子-α、干扰素-γ、白细胞介素-6、白细胞介素-1β和 Sox-10 的水平与疾病持续时间呈负相关。相反,促炎细胞因子或神经胶质标志物的水平与疾病严重程度、胃肠道症状或累积左旋多巴剂量之间均无相关性。存在和不存在肠路易体病理的患者之间,促炎细胞因子或神经胶质标志物的表达无显著差异。本研究结果提供了证据表明 PD 中存在肠内炎症,并进一步加强了外周炎症在疾病的发生和/或进展中的作用。